Indication
Intermediate Risk
1 clinical trial
1 product
Clinical trial
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI ScintigraphyStatus: Recruiting, Estimated PCD: 2031-02-01
Product
Systematic RAI-treatment